Back

B. Riley reiterates Buy on 4D Molecular with $37 target as Phase 3 begins

Verifying
  • B. Riley Securities reiterated its Buy rating and $37 price target for 4D Molecular Therapeutics.
  • 4D-150's modeled five-year procedure count is 8-12, versus 34 for aflibercept.
  • 4D Molecular Therapeutics began enrolling DME patients in the 4SIGHT Phase 3 trial.
The information on this website is generated using AI and we cannot guarantee its accuracy. Please use it as reference information only.
B. Riley reiterates Buy on 4D Molecular with $37 target as Phase 3 begins - CoinPost Terminal